New assurance rich, single-cell workflows for commercial cell and gene therapy laboratories
Watch Solentim's presentation at 5th Bioprocessing of Biotherapeutics and explore four technologies, that are designed for single cell cloning and assurance of monoclonality. Dr Duncan Borthwick from Solentim describes advances in clonally based workflows including cell line development, gene therapy and cell therapy.
This presentation includes:
Understanding the Regulatory and practical benefits of clonally-derived workflows
Latest approaches for antibody, iPSC derived cell therapy and viral vector approaches
Data management and quality considerations.
Duncan Borthwick PhD, Global Marketing Manager, Solentim
Duncan Borthwick has a PhD from the University of Edinburgh and University of North Carolina, Chapel Hill Since hanging up his lab coat 20+ years ago, Duncan has worked in the development of novel instrumentation and products. He heads the Product Management group at Solentim working closely with the R&D, biology and commercial teams working to define the next set of products to support the cell therapy community.
Please complete the form below and we’ll instantly send you an email with a link to the presentation:
Please double-check your ‘junk’ folder for the email from our [email protected] address.